Metabolic management of coronary heart disease: Adjunctive treatment with trimetazidine decreases QT dispersion in patients with a first acute myocardial infarction

Cardiovascular Drugs and Therapy

Volumn 15, Issue 4, 2001, Pages 315-321

  Kountouris, Evaggelos ^a   Pappa, Eugenia ^a   Pappas, Kostas ^a   Dimitroula, Vasiliki ^a   Karanikis, Paulos ^a   Tzimas, Thomas ^a   Siogas, Kostas ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Acute myocardial infarction; QT dispersion; Trimetazidine

Indexed keywords

PLACEBO; TRIMETAZIDINE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; ELECTROCARDIOGRAPHY; FEMALE; HEART INFARCTION; HEART INFARCTION SIZE; HEART RATE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ARRHYTHMIA; CORONARY DISEASE; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 0035205631     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012706630965     Document Type: Article

References (43)

1. Electrocardiographic indexes of dispersion of ventricular repolarization: An isolated heart validation study
2. Measurement, interpretation and clinical potential of QT dispersion
3. QT dispersion: An indication of arrhythmia risk in patients with long QT intervals
4. Assessment of QT dispersion in symptomatic patients with congenital long QT syndromes
5. Precordial QT interval dispersion as a marker of torsade de pointes: Disparate effects of class Ia antiarrhythmic drugs and amiodarone
6. Dynamics of QT dispersion during myocardial infarction and ischaemia
7. QT dispersion and early arrhythmic risk during acute myocardial infarction
8. Dispersion of QT interval in patients with and without susceptibility to ventricular arrhythmias after previous myocardial infarction
9. Reduction in QT interval dispersion by successful thrombolytic therapy in acute myocardial infarction
10. Multivariate associates of QT dispersion in patients with acute myocardial infarction: Primacy of patency status of the infarct-related artery. TEAM-3 Investigators. Third trial of thrombolysis with eminase in acute myocardial infarction
11. Acute effects of trimetazidine evaluated by exercise testing
12. Is the antianginal action of trimetazidine independent of hemodynamic changes
13. Improvement of long-term preservation of the isolated arrested rat heart by trimetazidine: Effects on the energy state and mitochondrial function
14. 31P-NMR spectroscopy in the isolated rat heart
15. Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells
16. Free radicals, thrombolytic therapy and myocardial infarction: Results of the EMIP-FR angiography substudy
17. Effect of trimetazidine on late potentials after acute myocardial infarction
18. The effect of trimetazidine on reperfusion arrhythmias in acute myocardial infarction
19. Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy. A double-blind, placebo-controlled, randomized trial
20. Rate-dependence of QT dispersion and the QT interval: Comparison of atrial pacing and exercise testing
21. An analysis of the time-relations of electrocardiograms
22. Trimetazidine reduces post-ischemic dysfunction in rat hearts by decreasing energy requirements during underperfusion
23. Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits
24. Limitation of infarct size by trimetazidine in the rabbit
25. I regulation in the rat isolated ventricular myocytes
26. i regulation in hypoxic cardiac myocytes from the rat
27. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme a thiolase
28. Effects of trimetazidine on in vivo coronary arterial platelet thrombosis
29. Dependence of temporal variability of ventricular recovery on myocardial fibrosis. Role of mechanoelectrical feedback?
30. Occurrence of sustained increase in QT dispersion following exercise in patients with residual myocardial ischemia after healing of anterior wall myocardial infarction
31. Outward currents in normal and hypertrophied feline ventricular myocytes
32. Effect of coronary angioplasty on precordial QT dispersion
33. Relation between QT dispersion and adenosine triphosphate stress thallium-201 single-photon emission computed tomographic imaging for detecting myocardial ischemia and scar
34. Metabolic management of ischemic heart disease: Clinical data with trimetazidine
35. Trimetazidine: A new concept in the treatment of angina. Comparison with propranolol in patients with stable angina
36. Trimetazidine European Multicenter Study versus propranolol in stable angina pectoris: Contribution of Holter electrocardiographic ambulatory monitoring
37. Chronic effects of trimetazidine on ergometric parameters in effort angina
38. Myocardial protection during percutaneous transluminal coronary angioplasty: Effects of trimetazidine
39. Variability of QT dispersion measurements in the surface electrocardiogram in patients with acute myocardial infarction and in normal subjects
40. QT dispersion and mortality after myocardial infarction
41. Assessment of QT dispersion for prediction of mortality or arrhythmic events after myocardial infarction: Results of a prospective, long-term follow-up study
42. Prognosis in myocardial infarction survivors with left ventricular dysfunction is predicted by electrocardiographic RR interval but not QT dispersion
43. The influence of atenolol and propafenone on QT interval dispersion in patients 3 months after myocardial infarction